WO2008060963A3 - Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer - Google Patents

Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer Download PDF

Info

Publication number
WO2008060963A3
WO2008060963A3 PCT/US2007/084177 US2007084177W WO2008060963A3 WO 2008060963 A3 WO2008060963 A3 WO 2008060963A3 US 2007084177 W US2007084177 W US 2007084177W WO 2008060963 A3 WO2008060963 A3 WO 2008060963A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulations
pharmaceutical
rapidly dissolving
dissolving layer
layered pharmaceutical
Prior art date
Application number
PCT/US2007/084177
Other languages
French (fr)
Other versions
WO2008060963A2 (en
Inventor
Anthony A Mckinney
Gary Tollefson
Eckard Weber
Rick Soltero
Original Assignee
Orexigen Therapeutics Inc
Anthony A Mckinney
Gary Tollefson
Eckard Weber
Rick Soltero
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39322569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008060963(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2007319471A priority Critical patent/AU2007319471B9/en
Priority to EP07864161A priority patent/EP2089005B1/en
Priority to KR1020157009741A priority patent/KR101654176B1/en
Priority to DE602007005402T priority patent/DE602007005402D1/en
Priority to KR1020097011226A priority patent/KR101479324B1/en
Priority to KR1020197010891A priority patent/KR20190042766A/en
Priority to MX2009004874A priority patent/MX2009004874A/en
Priority to KR1020167035323A priority patent/KR101971218B1/en
Priority to CA2668884A priority patent/CA2668884C/en
Priority to AT07864161T priority patent/ATE460925T1/en
Priority to DK07864161.0T priority patent/DK2089005T3/en
Priority to JP2009536494A priority patent/JP2010509367A/en
Priority to KR1020147021316A priority patent/KR101735466B1/en
Application filed by Orexigen Therapeutics Inc, Anthony A Mckinney, Gary Tollefson, Eckard Weber, Rick Soltero filed Critical Orexigen Therapeutics Inc
Publication of WO2008060963A2 publication Critical patent/WO2008060963A2/en
Publication of WO2008060963A3 publication Critical patent/WO2008060963A3/en
Priority to IL198577A priority patent/IL198577A/en
Priority to HK10101556.2A priority patent/HK1135026A1/en
Priority to IL233471A priority patent/IL233471A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.
PCT/US2007/084177 2006-11-09 2007-11-08 Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer WO2008060963A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP07864161A EP2089005B1 (en) 2006-11-09 2007-11-08 Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
AT07864161T ATE460925T1 (en) 2006-11-09 2007-11-08 MULTI-LAYER PHARMACEUTICAL FORMULATIONS WITH A RAPID DISSOLVING INTERLAYER
CA2668884A CA2668884C (en) 2006-11-09 2007-11-08 Layered pharmaceutical formulations
DE602007005402T DE602007005402D1 (en) 2006-11-09 2007-11-08 MULTILAYER PHARMACEUTICAL FORMULATIONS WITH A FAST RESOLVED INTERMEDIATE LAYER
KR1020097011226A KR101479324B1 (en) 2006-11-09 2007-11-08 Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
KR1020197010891A KR20190042766A (en) 2006-11-09 2007-11-08 Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
MX2009004874A MX2009004874A (en) 2006-11-09 2007-11-08 Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer.
KR1020167035323A KR101971218B1 (en) 2006-11-09 2007-11-08 Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
KR1020157009741A KR101654176B1 (en) 2006-11-09 2007-11-08 Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
AU2007319471A AU2007319471B9 (en) 2006-11-09 2007-11-08 Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
JP2009536494A JP2010509367A (en) 2006-11-09 2007-11-08 Laminated formulation
DK07864161.0T DK2089005T3 (en) 2006-11-09 2007-11-08 Layered pharmaceutical formulations comprising a rapidly dissolving intermediate layer
KR1020147021316A KR101735466B1 (en) 2006-11-09 2007-11-08 Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
IL198577A IL198577A (en) 2006-11-09 2009-05-05 Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
HK10101556.2A HK1135026A1 (en) 2006-11-09 2010-02-11 Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
IL233471A IL233471A0 (en) 2006-11-09 2014-07-01 Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86515706P 2006-11-09 2006-11-09
US60/865,157 2006-11-09

Publications (2)

Publication Number Publication Date
WO2008060963A2 WO2008060963A2 (en) 2008-05-22
WO2008060963A3 true WO2008060963A3 (en) 2008-07-10

Family

ID=39322569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/084177 WO2008060963A2 (en) 2006-11-09 2007-11-08 Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer

Country Status (19)

Country Link
US (6) US8088786B2 (en)
EP (1) EP2089005B1 (en)
JP (5) JP2010509367A (en)
KR (5) KR101479324B1 (en)
CN (1) CN101588795A (en)
AR (1) AR063959A1 (en)
AT (1) ATE460925T1 (en)
AU (1) AU2007319471B9 (en)
CA (1) CA2668884C (en)
CL (1) CL2007003245A1 (en)
DE (1) DE602007005402D1 (en)
DK (1) DK2089005T3 (en)
ES (1) ES2344440T3 (en)
HK (1) HK1135026A1 (en)
IL (2) IL198577A (en)
MX (1) MX2009004874A (en)
RU (1) RU2452471C2 (en)
TW (3) TW201811315A (en)
WO (1) WO2008060963A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119850B2 (en) 2013-12-06 2015-09-01 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
RU2350327C2 (en) 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Compounds causing weight loss
EP3132792B1 (en) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Composition and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR101479324B1 (en) * 2006-11-09 2015-01-05 오렉시젠 세러퓨틱스 인크. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
KR20140088619A (en) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. Unit dosage packages
AU2007319141B2 (en) 2006-11-17 2013-01-10 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
US8071557B2 (en) 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
MX2010012909A (en) * 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Methods for treating visceral fat conditions.
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
WO2010045522A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
US20100113581A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
WO2010045416A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
US20100113604A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
WO2010075275A1 (en) * 2008-12-23 2010-07-01 Usworldmeds Llc Selective release of non-racemic mixtures of two enantiomers from tablets and capsules
WO2010151503A2 (en) * 2009-06-25 2010-12-29 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2010151565A2 (en) * 2009-06-26 2010-12-29 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
US20100331999A1 (en) * 2009-06-29 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20110015663A1 (en) * 2009-07-17 2011-01-20 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20110082407A1 (en) * 2009-10-01 2011-04-07 Aronne Louis J Combination Therapies for the Treatment of Obesity
JP6196041B2 (en) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド Methods for providing weight loss therapy in patients with major depression
US20110280936A1 (en) * 2010-05-17 2011-11-17 Aptapharma, Inc. Self Breaking Tablets
US20120003312A1 (en) * 2010-06-30 2012-01-05 Aptapharma, Inc. Multilayer Minitablets with Different Release Rates
HUE053831T2 (en) 2010-12-03 2021-07-28 Nalpropion Pharmaceuticals Llc Increasing drug bioavailability in naltrexone therapy
US20130252995A1 (en) 2010-12-03 2013-09-26 Orexigen Therapeutics, Inc. Methods for reducing binge or compulsive eating
JP6110589B2 (en) * 2010-12-13 2017-04-05 第一三共ヘルスケア株式会社 Solid formulation containing loxoprofen sodium and clemastine fumarate
JP6112765B2 (en) * 2010-12-13 2017-04-12 第一三共ヘルスケア株式会社 Solid preparation containing loxoprofen sodium and dl-methylephedrine hydrochloride
JP6106359B2 (en) * 2010-12-13 2017-03-29 第一三共ヘルスケア株式会社 Solid formulation containing loxoprofen sodium and vitamin B1
JP6126780B2 (en) * 2010-12-13 2017-05-10 第一三共ヘルスケア株式会社 Solid formulation containing loxoprofen sodium and tranexamic acid
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
KR20140035331A (en) 2011-01-07 2014-03-21 엘셀릭스 테라퓨틱스 인코포레이티드 Chemosensory receptor ligand-based therapies
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US10576045B2 (en) 2011-02-16 2020-03-03 Nir Barak Low dosage combinations of fluoxetine and reboxetine for treating obesity
KR20190120430A (en) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 Biguanide compositions and methods of treating metabolic disorders
JP6175074B2 (en) 2012-01-06 2017-08-02 エルセリクス セラピューティクス インコーポレイテッド Compositions and methods for treating metabolic disorders
US20130237504A1 (en) * 2012-03-12 2013-09-12 Mehdi El Glaoui Pharmaceutical Forms and Methods for Designing the Same
MA37714A1 (en) 2012-06-06 2017-12-29 Orexigen Therapeutics Inc Methods of treating overweight and obesity
JP6160263B2 (en) * 2012-06-07 2017-07-12 大正製薬株式会社 Loxoprofen-containing pharmaceutical composition
US20160008375A1 (en) * 2013-03-01 2016-01-14 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical formulations comprising quetiapine and escitalopram
AU2015305215A1 (en) * 2014-08-22 2017-04-06 Medipath, Inc. Compositions and methods for cannabinoid coatings for use in drug delivery
WO2016125108A1 (en) * 2015-02-07 2016-08-11 Intas Pharmaceuticals Ltd. Bilayer pharmaceutical composition for the treatment of obesity
EP3253379A4 (en) * 2015-02-07 2018-10-10 Intas Pharmaceuticals Limited Pharmaceutical composition for the treatment of obesity
WO2016139530A2 (en) * 2015-03-04 2016-09-09 Arnold Forbes Compositions and methods for treating drug addiction
US10772917B2 (en) * 2015-03-11 2020-09-15 Ccs Ventures Limited Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (T2D)
CN108430465A (en) * 2015-09-30 2018-08-21 韦尔斯利医药有限公司 Composition, its manufacturing method and purposes for alleviating frequent micturition
EP3481381A4 (en) * 2016-07-06 2020-01-01 Durect Corporation Oral dosage form with drug composition, barrier layer and drug layer
CN111407734A (en) * 2019-01-05 2020-07-14 厦门赛诺邦格生物科技股份有限公司 Solid preparation of medicine for treating impotence and premature ejaculation
WO2021053542A1 (en) * 2019-09-20 2021-03-25 Dr. Reddy’S Laboratories Limited Pharmaceutical compositions for obesity management
KR102536511B1 (en) * 2020-06-25 2023-05-26 (주) 넥스팜코리아 Single-layer-tablet combined preparation of naltrexone sustained-release matrix formulation of bupropion sustained-release matrix formulation and the preparing method thereof
EP4243768A1 (en) * 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
KR20230113787A (en) 2020-12-01 2023-08-01 안테씨프 바이오벤쳐스 투 엘엘씨 Bupropion and dextromethorphan for reducing the risk of suicide in depressed patients
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
WO2024073334A1 (en) 2022-09-26 2024-04-04 Rose Research Center, Llc Combination for use in a method of preventing weight gain

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076493A1 (en) * 1999-06-14 2000-12-21 Thomas Najarian Combination therapy for effecting weight loss and treating obesity
WO2003097046A1 (en) * 2002-05-17 2003-11-27 Duke University Method for treating obesity
US20040254208A1 (en) * 2003-04-29 2004-12-16 Eckard Weber Compositions for affecting weight loss
WO2006088748A2 (en) * 2005-02-15 2006-08-24 Orexigen Therapeutics, Inc. Method for treating obesity
WO2007145863A2 (en) * 2006-06-05 2007-12-21 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885046A (en) 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
BE759838A (en) 1969-12-04 1971-06-03 Wellcome Found KETONES WITH BIOLOGICAL ACTIVITY
US3942641A (en) 1972-05-05 1976-03-09 Syntex Corporation Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
US4089855A (en) 1976-04-23 1978-05-16 Cornell Research Foundation, Inc. Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby
GB1557082A (en) * 1977-01-25 1979-12-05 Fisons Ltd Pharmaceutical mixture containing an antiinflammatory
US4218433A (en) * 1977-03-03 1980-08-19 Nippon Kayaku Kabushiki Kaisha Constant-rate eluting tablet and method of producing same
US4217353A (en) 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
IL58649A (en) 1978-11-10 1982-04-30 Beecham Group Ltd Pharmaceutical dispensing container
JPS58134019A (en) * 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd Slow-releasing triple-layered film pharmaceutical containing prostaglandin and its preparation
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US4895845A (en) 1986-09-15 1990-01-23 Seed John C Method of assisting weight loss
NL8800823A (en) 1987-04-10 1988-11-01 Sandoz Ag METHOD FOR USING DOPAMINE RECEPTOR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE AGONISTS
ES2058272T3 (en) 1987-05-04 1994-11-01 Lilly Co Eli FLUOXETINE USEFUL FOR THE TREATMENT OF DIABETES.
US5000886A (en) 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
DK469989D0 (en) * 1989-09-22 1989-09-22 Bukh Meditec PHARMACEUTICAL PREPARATION
EP0431663B1 (en) 1989-12-06 1994-01-12 Akzo Nobel N.V. Stabilized solutions of psychotropic agents
FR2657350B1 (en) 1990-01-19 1992-05-15 Centre Nat Rech Scient COMPOUNDS FOR ENCAPSULATION IN ERYTHROCYTES - NEW DERIVATIVES OF NALOXONE AND NALTREXONE.
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5213807A (en) * 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
US5403595A (en) 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
DE4136215A1 (en) 1991-11-02 1993-05-06 Ferring Arzneimittel Gmbh, 2300 Kiel, De USE OF OPIATE ANTAGONISTS FOR TREATING ENDOGENIC HYPERINSULINAEMIA
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1255522B (en) * 1992-09-24 1995-11-09 Ubaldo Conte COMPRESSED FOR THERAPEUTIC USE SUITABLE FOR SELLING ONE OR MORE ACTIVE SUBSTANCES WITH DIFFERENT SPEEDS
IT1256393B (en) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa MULTI-LAYER MATERIAL FORMS FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US6183778B1 (en) * 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
IT1265240B1 (en) * 1993-11-30 1996-10-31 Ekita Investments Nv CONTROLLED RELEASE PHARMACEUTICAL TABLET, LENTICULAR
AU3419995A (en) 1994-09-19 1996-04-09 Du Pont Merck Pharmaceutical Company, The Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
DE69709646T2 (en) 1996-03-12 2002-08-14 Alza Corp COMPOSITION AND DOSAGE WITH AN OPIOID ANTAGONIST
US5716976A (en) 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
CA2220768A1 (en) * 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds
IL121076A (en) 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
EP0915697B1 (en) 1996-06-28 2002-09-18 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
FR2758723B1 (en) 1997-01-28 1999-04-23 Sanofi Sa USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
ES2234139T3 (en) 1997-08-11 2005-06-16 Alza Corporation DOSAGE FORM OF AN ACTIVE PROLONGED RELEASE AGENT ADAPTED FOR GASTRIC RETENTION.
US6622036B1 (en) 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
JP2001518520A (en) 1997-10-03 2001-10-16 キャリー メディカル コーポレイション Composition for treating nicotine addiction comprising a nicotine receptor antagonist and an antidepressant or anxiolytic
US6652882B1 (en) 1997-10-06 2003-11-25 Intellipharmaceutics Corp Controlled release formulation containing bupropion
US6262049B1 (en) 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
IL127497A (en) 1997-12-18 2002-07-25 Pfizer Prod Inc Pharmaceutical compositions containing piperazinyl-heterocyclic compounds for treating psychiatric disorders
CN1149084C (en) 1997-12-26 2004-05-12 大日本制药株式会社 Medicine for treating neurodegenerative disease
NZ529316A (en) 1998-01-21 2004-05-28 Glaxo Group Ltd Pharmaceutically active morpholinol
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6048322A (en) 1998-04-15 2000-04-11 Kushida; Clete Morphometric measurement tool
US6153223A (en) 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US6033686A (en) 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6096341A (en) 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US20030144174A1 (en) 1998-12-09 2003-07-31 Miles B. Brennan Methods for identifying compounds useful for the regulation of body weight and associated conditions
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
PT1158973E (en) 1999-02-24 2005-07-29 Univ Cincinnati USE OF SULFAMATE DERIVATIVES FOR THE TREATMENT OF DRIVE CONTROL DISTURBLES
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6589553B2 (en) 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US6210716B1 (en) 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US20030035840A1 (en) 2001-02-08 2003-02-20 Boyong Li Controlled release oral dosage form
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6387956B1 (en) 1999-03-24 2002-05-14 University Of Cincinnati Methods of treating obsessive-compulsive spectrum disorders
JP2002541129A (en) 1999-04-01 2002-12-03 エスペリオン セラピューティクス インコーポレイテッド Ether compounds, compositions, and uses thereof
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
DE60039132D1 (en) 1999-04-06 2008-07-17 Sepracor Inc O-desmethylvenlafaxine succinate
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
DE19927688A1 (en) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Multi-layered tablet containing tramadole and diclofenac, useful for treating pain, has separating layer between active ingredient layers
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6071918A (en) 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6387403B1 (en) * 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
US6410736B1 (en) 1999-11-29 2002-06-25 Pfizer Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
US20020055512A1 (en) 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
JP2003520234A (en) 2000-01-22 2003-07-02 アルバート シャルマン How to treat drug addiction
US20020090615A1 (en) 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
AU4743601A (en) 2000-03-15 2001-09-24 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
WO2001068104A1 (en) 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
EP1272181A2 (en) 2000-04-13 2003-01-08 Synthon B.V. Modified release formulations containing a hypnotic agent
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
AU2001250646A1 (en) 2000-04-17 2001-10-30 Yamanouchi Pharmaceutical Co..Ltd. Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6191117B1 (en) 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
DE60134251D1 (en) 2000-09-18 2008-07-10 Sanos Bioscience As USE OF GLP-2 PEPTIDES
BR0115055A (en) 2000-10-30 2003-12-30 Ortho Mcneil Pharm Inc Combination therapy comprising anticonvulsant and antidiabetic agents
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
EP1404342A1 (en) 2001-04-26 2004-04-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
EP1262196A3 (en) 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
US6960357B2 (en) 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
DE60237087D1 (en) * 2001-06-01 2010-09-02 Pozen Inc PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAID
US6462237B1 (en) 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20030044462A1 (en) 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
ITFI20010230A1 (en) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TYPE II DIABETES
WO2003053402A1 (en) 2001-12-20 2003-07-03 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20040029941A1 (en) 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
US6972291B2 (en) 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
US20040258757A1 (en) 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US7086532B2 (en) 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
ATE487470T1 (en) 2002-09-11 2010-11-15 Elan Pharma Int Ltd GEL-STABILIZED ACTIVE COMPOSITIONS IN NANOPARTICLE SIZE
WO2004032980A1 (en) 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20040092504A1 (en) 2002-11-12 2004-05-13 Anuthep Benja-Athon Definitive medications for treating fibromyalgia
US6893660B2 (en) 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US20040115265A1 (en) * 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
JP2006514986A (en) * 2002-12-13 2006-05-18 シラグ・アクチエンゲゼルシヤフト Controlled release preparation comprising tramadol and topiramate
AU2003303631B2 (en) * 2002-12-26 2008-05-29 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Multilayer Dosage Forms Containing NSAIDs and Triptans
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US20040158194A1 (en) 2003-02-06 2004-08-12 Wolff Andy And Beiski Ben Z. Oral devices and methods for controlled drug release
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
MXPA05010636A (en) 2003-04-04 2005-12-12 Pharmacia Corp Oral extended release compressed tablets of multiparticulates.
RU2005135454A (en) 2003-05-16 2006-06-27 Пфайзер Продактс Инк. (Us) THERAPEUTIC COMBINATIONS OF ATYPICAL NEUROLEPTICS WITH GABA MODULATORS AND / OR ANTI-VASCULAR DRUGS
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US20050019385A1 (en) 2003-07-21 2005-01-27 Noven Pharmaceuticals, Inc. Composition and method for controlling drug delivery from silicone adhesive blends
WO2005009377A2 (en) 2003-07-23 2005-02-03 University Of Kentucky Research Foundation Novel oral bioavailable prodrugs
MEP3608A (en) 2003-08-08 2011-05-10 Biovail Lab Int Srl Modified-release tablet of bupropion hydrochloride
ES2318330T3 (en) 2003-08-08 2009-05-01 Elan Pharma International Limited NEW COMPOSITIONS OF METAXALONA.
US20050043773A1 (en) 2003-08-21 2005-02-24 Ivan Lieberburg Methods of improving the safety of zonisamide therapy
US20050043704A1 (en) 2003-08-21 2005-02-24 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050043705A1 (en) 2003-08-21 2005-02-24 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
EP1656148A4 (en) * 2003-08-21 2011-07-20 Duchesnay Inc Micronutrient supplement
US20050112198A1 (en) 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20050147664A1 (en) 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
US20070149451A1 (en) 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
US20050181049A1 (en) 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
CA2552221A1 (en) 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
US20060160750A1 (en) 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005070461A2 (en) * 2004-01-13 2005-08-04 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
CA2556214A1 (en) 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
WO2005092297A2 (en) 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
US20060100205A1 (en) 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
AU2005244151A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
US20050250838A1 (en) 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
CN101001619A (en) * 2004-08-03 2007-07-18 奥雷西根治疗公司 Combination of bupropion and a second compound for affectingweight loss
AU2005286733B2 (en) 2004-09-23 2009-11-05 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2006055854A2 (en) 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
JP2006232675A (en) * 2005-02-22 2006-09-07 Kowa Co Complex type solid preparation for dissolution in oral cavity
JP5369435B2 (en) * 2005-03-10 2013-12-18 大正製薬株式会社 Sugar coating
CA2606288A1 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
US20060246131A1 (en) 2005-04-28 2006-11-02 Cottlingham Elizabeth M Use of metformin to counteract weight gain associated with psychotropic medications
MX2007015052A (en) 2005-05-31 2008-01-18 Orexigen Therapeutics Inc Methods and compositions for managing psychotic disorders.
EP1907005A1 (en) 2005-07-27 2008-04-09 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP3132792B1 (en) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Composition and methods for increasing insulin sensitivity
WO2007089318A2 (en) 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US20070179168A1 (en) 2005-11-28 2007-08-02 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
WO2007062228A1 (en) * 2005-11-28 2007-05-31 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
WO2007084290A2 (en) 2006-01-12 2007-07-26 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US7915307B2 (en) 2006-07-20 2011-03-29 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US8682445B2 (en) 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
KR101479324B1 (en) 2006-11-09 2015-01-05 오렉시젠 세러퓨틱스 인크. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
KR20140088619A (en) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. Unit dosage packages
WO2009035473A2 (en) 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
US8071918B2 (en) 2007-10-30 2011-12-06 Prince Castle LLC. Controller for a food holding oven
MX2010012909A (en) * 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Methods for treating visceral fat conditions.
JP6196041B2 (en) * 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド Methods for providing weight loss therapy in patients with major depression

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076493A1 (en) * 1999-06-14 2000-12-21 Thomas Najarian Combination therapy for effecting weight loss and treating obesity
WO2003097046A1 (en) * 2002-05-17 2003-11-27 Duke University Method for treating obesity
US20040254208A1 (en) * 2003-04-29 2004-12-16 Eckard Weber Compositions for affecting weight loss
WO2006088748A2 (en) * 2005-02-15 2006-08-24 Orexigen Therapeutics, Inc. Method for treating obesity
WO2007145863A2 (en) * 2006-06-05 2007-12-21 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119850B2 (en) 2013-12-06 2015-09-01 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Also Published As

Publication number Publication date
CA2668884C (en) 2016-11-01
IL198577A0 (en) 2010-02-17
HK1135026A1 (en) 2010-05-28
KR20140101443A (en) 2014-08-19
AR063959A1 (en) 2009-03-04
JP2014088452A (en) 2014-05-15
EP2089005A2 (en) 2009-08-19
KR101479324B1 (en) 2015-01-05
KR101654176B1 (en) 2016-09-09
RU2009116835A (en) 2010-12-20
KR20170002660A (en) 2017-01-06
KR20190042766A (en) 2019-04-24
IL198577A (en) 2014-07-31
JP2010509367A (en) 2010-03-25
CN101588795A (en) 2009-11-25
KR101971218B1 (en) 2019-08-27
MX2009004874A (en) 2009-06-16
TW200829288A (en) 2008-07-16
JP2017057229A (en) 2017-03-23
AU2007319471A2 (en) 2009-07-02
US20120093889A1 (en) 2012-04-19
ES2344440T3 (en) 2010-08-26
AU2007319471B9 (en) 2012-10-04
US8318788B2 (en) 2012-11-27
KR101735466B1 (en) 2017-05-15
WO2008060963A2 (en) 2008-05-22
US20160338965A1 (en) 2016-11-24
CL2007003245A1 (en) 2008-03-28
JP6353089B2 (en) 2018-07-04
TW201603834A (en) 2016-02-01
AU2007319471B2 (en) 2012-09-27
ATE460925T1 (en) 2010-04-15
US20130177602A1 (en) 2013-07-11
US8088786B2 (en) 2012-01-03
DE602007005402D1 (en) 2010-04-29
JP5908008B2 (en) 2016-04-26
CA2668884A1 (en) 2008-05-22
US20150164806A1 (en) 2015-06-18
IL233471A0 (en) 2014-08-31
EP2089005B1 (en) 2010-03-17
JP2018127499A (en) 2018-08-16
JP2016029106A (en) 2016-03-03
KR20150046390A (en) 2015-04-29
TW201811315A (en) 2018-04-01
AU2007319471A1 (en) 2008-05-22
TWI504419B (en) 2015-10-21
KR20090094263A (en) 2009-09-04
RU2452471C2 (en) 2012-06-10
US20230301922A1 (en) 2023-09-28
JP6633130B2 (en) 2020-01-22
TWI609702B (en) 2018-01-01
JP6240140B2 (en) 2017-11-29
DK2089005T3 (en) 2010-07-19
US20080113026A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2008060963A3 (en) Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
WO2007073702A3 (en) Multi-layered tablet with triple release combination
WO2007002597A3 (en) Modified-release formulations of a bupropion salt
WO2008011169A3 (en) Controlled release formulations and associated methods
WO2007103557A3 (en) Coating capsules with active pharmaceutical ingredients
WO2007036952A3 (en) Novel sustained release dosage form
JP2010509367A5 (en)
WO2009059701A3 (en) Sustained release tablets with hydromorphone
WO2008124617A3 (en) Rapidly dissolving pharmaceutical compositions comprising pullulan
HUE039382T2 (en) Liquid formulations comprising an active agent, glycerine and sorbitol
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
WO2007052299A3 (en) Controlled release formulation
WO2005097064A3 (en) Taste-masked drugs in rupturing multiparticulates
IL193274A0 (en) Pharmaceutical formulation for aerosols, comprising two or more active agents and at least one surfactant
WO2003039519A3 (en) Dual controlled release dosage form
WO2010037854A3 (en) Alcohol-resistant sustained-release oral pharmaceutical form based on microgranules
WO2009062746A3 (en) Topical drugs for use in antifungal therapy
WO2007048027A3 (en) Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2006092230A3 (en) Protein-binding camptothecin peptide derivatives and medicaments comprising the same
WO2006030402A3 (en) Dual compartment osmotic delivery device
WO2006008173A3 (en) Pharmaceutical formulations for inhalation
CL2007003130A1 (en) USE OF AN IMMEDIATE RELEASE FORMULATION WITH A SELECTED ACTIVE INGREDIENT OF PRAMIPEXOL, PRAMIPEXOL HYDROCLORIDE, PRAMIPEXOL MONOHIDRATE DIHYDROCLORIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THIS, FOR THE TREATMENT OF THE DISEASE
PL1795186T5 (en) Flupirtin comprising medicament formulation with a controlled release of the active agent
WO2009038095A1 (en) Composition comprising sesamin component and vitamin b1 component
WO2010052466A8 (en) Pharmaceutical aerosol composition

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780049440.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07864161

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 198577

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2668884

Country of ref document: CA

Ref document number: MX/A/2009/004874

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009536494

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007864161

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3269/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007319471

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020097011226

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009116835

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2007319471

Country of ref document: AU

Date of ref document: 20071108

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 233471

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020147021316

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1020157009741

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1020167035323

Country of ref document: KR